RECURSION PHARMACEUTICALS, INC. Deferred Tax Liabilities, Intangible Assets
RECURSION PHARMACEUTICALS, INC. (RXRX) had Deferred Tax Liabilities, Intangible Assets of $56.30 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-25
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $56.30M.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $67.14M.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $5.27M.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $0.00.
| Period end | Deferred Tax Liabilities, Intangible Assets |
|---|---|
| 2025-12-31 | $56.30M 10-K · filed 2026-02-25 |
| 2024-12-31 | $67.14M 10-K · filed 2026-02-25 |
| 2023-12-31 | $5.27M 10-K · filed 2025-02-28 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |